Skip to content
Screener

Celldex Therapeutics CLDX Total Liabilities & Equity

Total Liabilities & Equity at other companies

Eli Lilly logo
Eli LillyLLY
$142.28B+41.0%
Pfizer logo
PfizerPFE
$207.62B-0.2%
Rogers Corporation logo
Rogers CorporationROG
$1.45B-0.3%
Amgen logo
AmgenAMGN
$95.64B+8.8%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$41.73B+9.2%
Incyte logo
IncyteINCY
$7.87B+35.2%

Other financials

Income statement

See full
Revenue$22.0K-97.0%
Operating income-$80.6M-26.3%
Net income-$73.5M-29.9%
EPS (diluted)-$0.94-10.6%

Balance sheet

See full
Cash & equivalents$47.5M+106%
Total debt$4.9M+61.8%
Total equity$714.6M+9.0%
Total assets$782.3M+13.0%

Cash flow

See full
Operating cash flow-$57.4M-30.5%
CapEx$3.2M+337%
Free cash flow-$60.6M-35.4%

Valuation

See full
Market cap$3.26B+129%
Enterprise value$3.22B+129%
P/S20,646.4×+20,401×

Profitability

See full
Operating margin-206,220.3%-210,440pp
Net margin-190,220.9%-193,797pp
FCF margin-153,231%-156,630pp

Returns & leverage

See full
Return on equity-43.9%+70.0pp
Debt / equity0.0×
Current ratio11.8×-7.8×

Where this comes from

Reported directly by Celldex Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-091984
Line itemJune 30, 2026December 31, 2025
Stockholders’ equity:
Convertible preferred stock, $.01 par value; 3,000,000 shares authorized; no shares issued and outstanding at June 30, 2026 and December 31, 2025
Common stock, $.001 par value; 297,000,000 shares authorized; 78,500,173 and 66,549,442 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively7967
Additional paid-in capital2,679,3562,337,453
Accumulated other comprehensive income1,2983,626
Accumulated deficit(1,966,169)(1,813,981)
Total stockholders’ equity714,564527,165
Total liabilities and stockholders’ equity$782,349$582,983

Item 1. Unaudited Financial Statements

FAQ

What is Celldex Therapeutics's total liabilities & equity?
Celldex Therapeutics (CLDX) reported total liabilities & equity of $782.35M in Q2 2026.
How has Celldex Therapeutics's total liabilities & equity changed year-over-year?
Celldex Therapeutics's total liabilities & equity increased by 13.0% year-over-year, from $692.41M to $782.35M.
What is the long-term trend for Celldex Therapeutics's total liabilities & equity?
Over 5 years (2020 to 2025), Celldex Therapeutics's total liabilities & equity has grown at a 19.8% compound annual growth rate (CAGR), from $235.84M to $582.98M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Celldex Therapeutics's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude